Sionna Therapeutics, Inc. SION R2K
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -29.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SION Sionna Therapeutics, Inc. R2K | 42.82 | - | $1.93B | - | -28.32% | -26.74% | - | -29.02% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 19.66M | 21.91M | 23.80M | 23.61M | 29.60M |
| Operating Income | -13.15M | -11.29M | -27.98M | - | -19.66M | -21.91M | -23.80M | -23.61M | -29.60M |
| EBITDA | - | - | - | - | -19.23M | -21.43M | -23.29M | -23.46M | -29.11M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -16.48M | -18.07M | -20.28M | -20.44M | -26.78M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -11.85M | -8.55M | -25.44M | - | -16.48M | -18.07M | -20.28M | -20.44M | -26.78M |
| Diluted EPS | -3,840.00 | -2,710.00 | -5.67 | - | -0.62 | -0.41 | -0.46 | -0.46 | -0.60 |
| R&D Expense | 10.22M | 8.23M | 24.58M | - | 13.67M | 15.38M | 16.04M | - | 18.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 41.37M | 50.33M | 70.56M | 88.98M |
| Operating Income | -41.37M | -50.33M | -70.56M | -88.98M |
| EBITDA | -41.25M | -49.75M | -69.89M | -88.33M |
| Interest Expense | - | - | - | - |
| Pretax Income | -40.24M | -47.26M | -61.69M | -75.27M |
| Tax Provision | - | - | - | - |
| Net Income | -40.24M | -47.26M | -61.69M | -75.27M |
| Diluted EPS | -2.32 | -1.70 | -1.45 | - |
| R&D Expense | - | - | 57.29M | 60.26M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -29.02% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +212.78% |
| 6 Months: | -3.30% |
| 3 Months: | +17.19% |
| 1 Month: | +14.40% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 87.37M | 51.95M | 185.75M | 325.95M |
| Current Assets | 83.83M | 39.21M | 150.99M | 241.42M |
| Cash & Equivalents | 54.84M | 38.52M | 37.79M | 58.45M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 157.29M | 166.83M | 349.46M | 19.12M |
| Current Liabilities | 8.25M | 8.04M | 10.42M | 11.71M |
| Long Term Debt | - | - | - | - |
| Total Debt | 0 | 10.48M | 9.75M | 8.68M |
| Total Equity | -69.92M | -114.88M | -163.71M | 306.83M |
| Shares Outstanding | 42.44M | 42.44M | 42.44M | 44.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -36.07M | -43.70M | -52.79M | -66.30M |
| Investing Cash Flow | -29.26M | 27.35M | -126.91M | -118.75M |
| Financing Cash Flow | 110.86M | 31.00K | 178.97M | 205.71M |
| Capital Expenditure | -1.87M | -1.12M | -27.00K | -377.00K |
| Free Cash Flow | -37.94M | -44.81M | -52.81M | -66.67M |
| Net Change in Cash | 45.52M | -16.32M | -733.00K | 20.66M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 57.5% | 41.1% | 37.7% | -24.5% |
| ROCE % | -52.3% | -114.6% | -40.2% | -28.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 21.94% | 9.91M | $424.13M |
| 2 | TPG GP A, LLC | 14.39% | 6.49M | $278.11M |
| 3 | Orbimed Advisors LLC. | 7.82% | 3.53M | $151.18M |
| 4 | Viking Global Investors, L.P. | 7.08% | 3.20M | $136.82M |
| 5 | Atlas Venture Life Science Advisors, LLC | 6.63% | 3.00M | $128.27M |
| 6 | Enavate Sciences Gp, LLC | 5.49% | 2.48M | $106.11M |
| 7 | JPMORGAN CHASE & CO | 3.24% | 1.47M | $62.73M |
| 8 | Jennison Associates LLC | 3.21% | 1.45M | $62.14M |
| 9 | Blackrock Inc. | 2.87% | 1.30M | $55.49M |
| 10 | Citadel Advisors Llc | 2.58% | 1.17M | $49.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SION